Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Luís Coelho; Fatima Falcão; Pedro Póvoa; Erica Viegas; Antonio Pais Martins; Eduarda Carmo; Candida Fonseca; Luis Campos; Kamal Mansinho; Inês Carmo; Joana Soares; Mariana Solano; Dina Mendes; Ana Cláudia Miranda; Antonio Carvalho; Ana Mirco; Helena Farinha; Isabel Aldir; José Correia

doi:10.1038/s41598-023-31544-5

Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Luís Coelho^*, Fatima Falcão, Pedro Póvoa, Erica Viegas, Antonio Pais Martins, Eduarda Carmo, Candida Fonseca, Luis Campos, Kamal Mansinho, Inês Carmo, Joana Soares, Mariana Solano, Dina Mendes, Ana Cláudia Miranda, Antonio Carvalho, Ana Mirco, Helena Farinha, Isabel Aldir, José Correia

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Klinisk Epidemiologi (Odense)

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

16 Downloads (Pure)

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7–12.8; 14.9–17.1; p =.016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.

Originalsprog	Engelsk
Artikelnummer	4482
Tidsskrift	Scientific Reports
Vol/bind	13
Antal sider	6
ISSN	2045-2322
DOI	https://doi.org/10.1038/s41598-023-31544-5
Status	Udgivet - 18. mar. 2023

Bibliografisk note

Publisher Copyright:
© 2023, The Author(s).

Dokumenter og links

10.1038/s41598-023-31544-5Licens: CC BY

Open Access VersionForlagets udgivne version, 1,13 MBLicens: CC BY

Citationsformater

Coelho, L., Falcão, F., Póvoa, P., Viegas, E., Martins, A. P., Carmo, E., Fonseca, C., Campos, L., Mansinho, K., Carmo, I., Soares, J., Solano, M., Mendes, D., Miranda, A. C., Carvalho, A., Mirco, A., Farinha, H., Aldir, I., & Correia, J. (2023). Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients. Scientific Reports, 13, Artikel 4482. https://doi.org/10.1038/s41598-023-31544-5

@article{4f9d4777bc2c41388613d77d6f19d96d,

title = "Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients",

abstract = "Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7–12.8; 14.9–17.1; p =.016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.",

keywords = "Adenosine Monophosphate/therapeutic use, Adrenal Cortex Hormones/therapeutic use, Adult, Alanine/therapeutic use, Antiviral Agents/therapeutic use, COVID-19, COVID-19 Drug Treatment, Humans, Respiratory Insufficiency/chemically induced",

author = "Lu{\'i}s Coelho and Fatima Falc{\~a}o and Pedro P{\'o}voa and Erica Viegas and Martins, {Antonio Pais} and Eduarda Carmo and Candida Fonseca and Luis Campos and Kamal Mansinho and In{\^e}s Carmo and Joana Soares and Mariana Solano and Dina Mendes and Miranda, {Ana Cl{\'a}udia} and Antonio Carvalho and Ana Mirco and Helena Farinha and Isabel Aldir and Jos{\'e} Correia",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = mar,

day = "18",

doi = "10.1038/s41598-023-31544-5",

language = "English",

volume = "13",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

Coelho, L, Falcão, F, Póvoa, P, Viegas, E, Martins, AP, Carmo, E, Fonseca, C, Campos, L, Mansinho, K, Carmo, I, Soares, J, Solano, M, Mendes, D, Miranda, AC, Carvalho, A, Mirco, A, Farinha, H, Aldir, I & Correia, J 2023, 'Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients', Scientific Reports, bind 13, 4482. https://doi.org/10.1038/s41598-023-31544-5

TY - JOUR

T1 - Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

AU - Coelho, Luís

AU - Falcão, Fatima

AU - Póvoa, Pedro

AU - Viegas, Erica

AU - Martins, Antonio Pais

AU - Carmo, Eduarda

AU - Fonseca, Candida

AU - Campos, Luis

AU - Mansinho, Kamal

AU - Carmo, Inês

AU - Soares, Joana

AU - Solano, Mariana

AU - Mendes, Dina

AU - Miranda, Ana Cláudia

AU - Carvalho, Antonio

AU - Mirco, Ana

AU - Farinha, Helena

AU - Aldir, Isabel

AU - Correia, José

PY - 2023/3/18

Y1 - 2023/3/18

N2 - Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7–12.8; 14.9–17.1; p =.016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.

AB - Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7–12.8; 14.9–17.1; p =.016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.

KW - Adenosine Monophosphate/therapeutic use

KW - Adrenal Cortex Hormones/therapeutic use

KW - Adult

KW - Alanine/therapeutic use

KW - Antiviral Agents/therapeutic use

KW - COVID-19

KW - COVID-19 Drug Treatment

KW - Humans

KW - Respiratory Insufficiency/chemically induced

U2 - 10.1038/s41598-023-31544-5

DO - 10.1038/s41598-023-31544-5

M3 - Journal article

C2 - 36934143

AN - SCOPUS:85150666465

SN - 2045-2322

VL - 13

JO - Scientific Reports

JF - Scientific Reports

M1 - 4482

ER -

Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Abstract

Bibliografisk note

Dokumenter og links

Fingeraftryk

Citationsformater